ArticleNature communications2022

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas.

Paul K Paik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.